Comparing RYTHM (NASDAQ:RYM) and Lifecore Biomedical (NASDAQ:LFCR)

RYTHM (NASDAQ:RYM) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Institutional & Insider Ownership

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares RYTHM and Lifecore Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RYTHM	9.84%	21.25%	5.51%
Lifecore Biomedical	-56.80%	N/A	-29.53%

Volatility and Risk

RYTHM has a beta of 9.94, meaning that its share price is 894% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.

Valuation & Earnings

This table compares RYTHM and Lifecore Biomedical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28 million	2.02	-$33.26 million	($5.27)	-3.05
Lifecore Biomedical	$128.87 million	1.88	-$70.51 million	($1.86)	-3.44

RYTHM has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for RYTHM and Lifecore Biomedical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1	0	0	0	1.00
Lifecore Biomedical	2	3	0	0	1.60

Lifecore Biomedical has a consensus target price of $6.50, indicating a potential upside of 1.56%. Given Lifecore Biomedical’s stronger consensus rating and higher probable upside, analysts plainly believe Lifecore Biomedical is more favorable than RYTHM.

About RYTHM

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction.

About Lifecore Biomedical

Lifecore Biomedical, Inc. is a contract development and manufacturing organization that provides development, formulation, aseptic filling, packaging and other manufacturing services for pharmaceutical and biopharmaceutical companies. The company specializes in complex sterile injectable products and supports customers from development through commercial production. Lifecore has particular expertise in hyaluronic acid, a naturally occurring substance used in ophthalmic, orthopedic, aesthetic and other medical applications.